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1. Abstract 
Introduction: Tears of the rotator cuff muscle lead to retraction and irreversible degen-
eration of the muscle, that makes repairs with current methods difficult or to some ex-
tent not possible. Different approaches to this matter have been made, for example me-
chanical re-lengthening or pharmacological treatment. Other studies have investigated 
the effect of the pharmacological inhibition of the calcium-dependent protease calpain 
with calpeptin, for preventing muscle atrophy. Yet the role of calpeptin in muscles is un-
clear. This is what we dedicated our research for. 
Material and Methods: computer tomography scans of 18 female, Swiss alpine sheep 
were analysed after releasing the infraspinatus muscle of the right shoulder. The sheep 
were divided in two groups, one group (n 12) was administrated calpeptin, the other 
group (n 6) was administrated an adjuvant and served as a control group. The 
pathomechanical changes have been studied histologically and with the use of comput-
er tomography during six weeks after muscle release. In the scans and probes were the 
muscle length, cross sectional area, fatty infiltration and muscle retraction evaluated. 
Results: The muscle length decreases over the time and ranges from 16.38 ± 0.17 to 
14.87 ± 0.13 cm in the calpeptin (CALP) and 15.51 ± 0.39 to 14.20 ± 0.42 cm in the 
control group. Significant differences between the two groups can be seen in week 0 
and week 4 (P < 0.05). The cross sectional area remains mainly constant and ranges 
from 14.61 ± 0.62 to 13.54 ± 0.62 cm2 in the CALP and 15.30 ± 0.75 to 13.44 ± 0.79 
cm2 in the control group. The muscle densitiy of the muscle decreases persistently in 
both groups in the coronal plane as well as in the transverse plane. The retraction of the 
bone fragment increases constantly over time in both groups and ranges from 0.37 ± 
0.03 cm to 1.5 ± 0.19cm in the CALP and 0.70 ± 0.23 to 1.64 ± 0.28 cm in the control 
group. There is a significant difference between the two groups in week 0 (P < 0.05%). 
The contralateral, un-involved side shows constant parameters over the time in both 
groups. 
Conclusion: With calpeptin a positive effect on muscle length and retraction can be 
shown mainly in the first hour after tendon release. The results show that the muscle 
retracts quickly probably in association with calpain. Since mechanical factors regulate 
the muscle mass, there is a possibility of calpeptin, by sustaining the muscle length, 
preventing degenerative process.   
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The pathophysiological mechanisms underlying the effects of calpeptin in muscle fibres 
remain unclear. 
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2. Abbreviations 
 
CALP    calpeptin 
CLAT    contralateral 
CSA    cross sectional area 
CT    computer tomography 
HU    Hounsfield unit 
IGF     insulin-like growth factor 
OP    operated  
ROI    region of interest 
DMSO   Dimethylsulfoxid 
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3. Introduction 
Full thickness tears of the rotator cuff can lead to retraction and subsequent irreversible 
degeneration of the detached muscle; those are the main limiting factors of established 
repairing procedures [1, 2] of the rotator cuff. 
Previous studies have shown, that retraction is mainly caused by shortening of the 
muscle and then by shortening of the tendon [1]. Once retraction has taken place, it is 
followed by muscle atrophy and irreversible fatty infiltration [1-3]. These irreversible 
changes make a repair in an advanced stage of the rotator cuff tear difficult or even to 
some extent not possible: the muscle needs to be overstretched, leading to damage of 
fibres and increasing the fatty muscle infiltration [1-3]. Even when repair has succeeded 
the structural changes of the muscle remain mostly irrecoverable [2, 3]. This issue 
leaves two approaches: either repair needs to be conducted before retraction has taken 
place or new treatments procedures are necessary.  
The latter has been approached by several researchers with different methods, for ex-
ample with continuous musculotendinous traction [3], that showed success in re-
lengthening the muscle in sheep – but only when fatty infiltration was not advanced be-
yond 30% (Goutallier stage 1). In that study fatty infiltration could not be reversed, but 
progression of fatty infiltration could be prevented [3] by muscle re-lengthening. Another 
approach focuses on pharmacological treatment with anabolic steroids or insulin-like 
growth factor (IGF) [4] or the combination of both pharmacological and mechanical 
stimulation [5]. Finally, most of them came to the conclusion, that you can prevent de-
generative changes from happening, but you cannot reverse them once they have oc-
curred.  
Recent studies investigated the efficiency of the pharmacological inhibition of the calci-
um-dependent protease calpain with calpeptin, for preventing muscle atrophy [6, 7]. 
Calpain stands for a family of three proteases that are central to myofibrillar protein deg-
radation through its effect on the proteolysis of the Z-disks that hold sarcomeres in reg-
ister [8-10]. The critical role of calpain in muscle wasting is emphasized by the recent 
identification that gene defects in calpain 3 produce muscle dystrophy [11]. Interestingly, 
calpain also regulates the differentiation of adipocytes in culture [12]. Besides the de-
scription of its implication, the (patho-) physiological role of calpain activation in skeletal 
muscle is not clear [13]. This is where we aim our investigations.  
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The purpose of this study was to test two different hypotheses: First, that calpain-
inhibitor leads to less muscle atrophy and fatty infiltration after tendon detachment, and 
second, that calpeptin influences muscle length over a reduction of the muscular 
strength. 
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4. Material and Methods 
4.1. Sheep 
An accepted model for chronic rotator cuff injuries is the sheep, due to its similarity of 
the infraspinatus muscle to the human supraspinatus muscle [14]. The study was car-
ried out with 18 female, white Swiss alpine sheep from the plant Staffelegghof AG, Küt-
tingen Switzerland, not pregnant, at the age of 26.7 (±1.4) months and the weight of 
62.8 (±2.5) kg. All sheep were vaccinated against clostridia, pasteurella and foot rot. 
The infraspinatus muscle was released and the sheep were arranged in two experi-
mental groups. 12 sheep were administered calpeptin (CALP), whereas 6 sheep were 
administered an adjuvant as a control. (Table 1) 
One sheep in the CALP group was excluded due to death after week 2. 
4.2. Experiment Protocol and Timetable 
As mentioned before the sheep were divided into two groups, one group with CALP 
administration and another group with adjuvant administration, which served as a con-
trol group. Within the groups the right infraspinatus muscle was released and an osmot-
ic pump (Alzet® 2ML4), with the flow rate of 2.5 µl/h giving 12.5 mg/ml substrate in 75% 
DMSO, was inserted. The contralateral side served as a control. A computer tomogra-
phy scan and biopsy were taken within an hour after tendon release and after the fol-
lowing two, four and six weeks. The muscle length, cross secitonal area, fatty muscle 
Infiltration in the coronal and transverse plane and the bone fragment retraction were 
measured and evaluated. After the killing the entire muscle was removed and histologi-
cally investigated. (Figure 1) 
Surgeries were performed by the upper extremity team of Balgrist University Hospital 
(surgeon: PD. Dr. med. Karl Wieser) and a veterinary surgeon at the Vetsuisse Faculty 
Zurich (surgeon: Dr. med. vet, Karina Klein, DVM-PhD). In all sheep, the infraspinatus 
tendon at the right shoulder was released by performing osteotomy of the greater tuber-
osity of the humerus bone. To administer calpeptin locally, the osmotic pumps were in-
serted with catheters into the muscle at 2.5 cm proximally to the severed infraspinatus 
tendon. The tube was fastened in place through chinese finger sutures (suture is posi-
tioned into the muscle tissue and the ends are wrapped around the tube in a spiral pat-
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tern and then tied). To prevent spontaneous healing of the infraspinatus tendon a silicon 
rubber tube encased the musculotendinous end. 
 
Sheep All n=18 CALP n=12 control n=6 
Age [month] 26.7 ± 1.4 26.7 ± 1.4 26.7 ± 1.4 
Weight [kg] 61.8 ± 2.5 64.8 ± 6.6 62.0 ± 2.1 
 
 
 
 
 
 
 
 
week 6 
CT, biopsy 
week 4 
CT, biopsy 
week 2 
CT, biopsy 
week 0 
Tendon release 
Implantation of pump 
CT, biopsy 
preoperativ 18 sheep 
Group I (n=12) 
calpeptin 
Group I (n=12)  
pump 
replacement 
Group I (n=11) 
death of 1 
sheep 
Killing 
Group II (n=6) 
control 
 Group II (n=6) 
pump 
replacement 
Group II (n=6) 
Killing 
Figure 1. Timetable 
Table 1. 18 swiss alpine sheep divided in two experimental groups. One group re-
ceived the CALP administration, the other group served as control and received the ad-
juvant administration. 
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4.3. Imaging 
Computed Tomography (CT): 
A 40-slice CT scanner was used (SOMATOM Sensation Open; Siemens Medical Solu-
tions, Erlangen, Germany). The sheep were scanned between November 2014 and 
March 2015. All sheep received general anaesthesia for examination in the scanner and 
were positioned on their back. Image acquisition parameters included an x-ray tube 
voltage of 120 KVp, a current of 150 mAs and a slice thickness of 1 mm.  
4.4. Measurements 
The transverse CT images in soft tissue kernel (B20s) were checked for symmetrical 
scapula position (left and right) and reconstructed in the coronal and sagittal plane in 
each sheep by a fellowship trained, musculoskeletal radiologist (blinded for review pur-
poses). In case of oblique or asymmetrical scapula position the images were recon-
structed as well in the transverse plane in order to get symmetric scapula positions for 
measurements. 
All measurements were performed by a medical student (blinded for review purposes 
2015) after a detailed measurement training session, supervised by a fellowship trained 
musculoskeletal radiologist (blinded for review purposes). The following measurements 
were performed in all sheep of the CALP-group and the control-group. In every sheep 
the measurements were done on both sides, on the operated (OP) and the non-involved 
contralateral side (CLAT) side. (Figure 2) 
4.4.1. Muscle Length  
The length of the infraspinatus muscle was measured (in cm) in the transverse plane: 
On the OP side the measurement started from the bone fragment to the point where the 
scapular spine merges into the scapular body. On the CLAT side the measurement 
started from tendon insertion at the greater tubercle to the analogue point where scapu-
lar spine merges into the scapular body (Figure 3). 
4.4.2. Cross Sectional Area  
The cross sectional Area (CSA, in cm2) was measured in the coronal plane (Figure 4): 
First, the pump was localized in the transverse plane (Figure 5). Afterwards, the coronal 
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slice lying 1 cm anterior to the anterior pump end was chosen. On that slice the infrasp-
inatus muscle borders were circled for CSA assessment.  
4.4.3. Fatty Muscle Infiltration 
The density of the infraspinatus muscle was assessed using the Hounsfield units (HU). 
The HU correlates with the muscle lipid content [15, 16] and is an established form to 
measure fatty infiltration in CT scans. 
Based on HU the muscle was graded for fatty infiltration according to the Goutallier 
classification, as described previously [17]: stage 0= > 50 HU = < 10% fat, stage 1= 35-
49 HU = 11-30% fat, stage 2= 25-34 HU = 30-45% fat, stage 3= 15-25 HU = 45-55% 
fat, stage 4= <14 HU = > 55% fat.  
The density was measured twice, in the coronal and in the transverse plane. The meas-
urements were performed very carefully, excluding adjacent bony borders and air arte-
facts  - in order to avoid false HU measurements.  
4.4.3.1. Coronal 
The measurements were performed on the same coronal slice as chosen for CSA as-
sessment (Figure 4). The borders of the infraspinatus muscle defined the region of in-
terest (ROI) and the Hounsfield units were assessed.  
4.4.3.2. Transverse 
Starting with the above chosen coronal image slice on each side a corresponding trans-
verse slice was chosen - running perpendicular to the coronal plane and through the 
centre of the infraspinatus muscle belly (Figure 6). On this transverse image the borders 
of the muscle belly defined the borders of the ROI (Figure 7). 
4.4.4. Muscle Retraction  
On the operated side only, the musculotendinous retraction was measured as the dis-
tance of the bone chip to its original insertion side on the humeral head (Figure 8). 
4.5. Statistical Analysis 
Statistical analysis of the data was performed using the software IBM SPSS Statistics 
22 for Mac. The level of significance was set at P < 0.05. The data was tested for nor-
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mal distribution with the Shapiro-Wilk test, before either parametric or nonparametric 
tests were performed. The different groups were compared using the unpaired t test 
along with the assessment of equality of variances by the Levene’s test or compared 
using the Mann-Whitney U test. Missing data were excluded from the analysis. (Table 2) 
4.6. Ethics 
The study was submitted to the veterinary department of canton Zurich (application 
number ZH219/2014). The experiment was carried out after their approval and with the 
most possible ethical husbandry. 
 
Figure 2.  CT scans showing the infraspinatus muscle on both sides, the operated 
and the control side. The pump is situated on the operated right side (arrow), lying in 
the infraspinatus muscle belly, adjacent to the scapular spine (asterisk), H = Humeral 
head. (a) CT of the transverse plane. (b) CT of the coronal plane. 
* 
H 
a b 
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Figure 3.  Transverse CT scan show-
ing the measurements of muscle length 
on both sides: the OP side (a) and the 
CLAT side (b) 
a 
b 
Figure 4.  Coronal reconstructed CT 
image showing measurements of cross 
sectional area and density on both sides.  
Figure 5.  Pump in trans-
verse plane and corresponding 
measurement point for coronal 
area and density (dashed line). 
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Figure 6.  Coronal reconstructed CT 
image showing the four quadrants in the 
infraspinatus muscle. The muscle centre 
(*) in the coronal plane served as refer-
ence point for the transverse plane in or-
der to conduct density measurements.  
* 
Figure 8.  Transverse CT scan 
showing the measurement of muscle 
retraction on the operated right side. 
Figure 7.  Transverse density meas-
ured in transverse plane on both sides 
for evaluation of the fatty infiltration. 
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5. Results 
5.1. Muscle Length 
Immediately after tendon release the measurements of the CT show a decrease of the 
muscle length from its original length on the OP side in both groups (mean ± standard 
error): The muscle length at this time in the CALP group was 16.38 ± 0.17 cm and in the 
control group 15.51 ± 0.39 cm. There is a significant difference (P < 0.05) between the 
CALP and the control group. In week 2 the muscle shortens more to a length of 15.57 ± 
0.12 cm in the CALP group and 14.87 ± 0.44 cm in the control group. There is no signif-
icance difference between the groups. While in week 4 there is a significant (P < 0.05) 
difference between the CALP and the control group. At this point the muscle length 
amounts to 15.35 ± 0.16 cm in the CALP group and 14.45 ± 0.31 cm in the control 
group. There is no significant difference between the groups in week 6, where the mus-
cle length decreases to 14.87 ± 0.13 cm in the CALP group and 14.20 ± 0.42 cm in the 
control group (Figure 9a).  
The CLAT, un-involved side shows a constant muscle length over the time in both 
groups with no significant differences.  (Figure 9b)  
 
Figure 9. Mean muscle length over time measured in CT. Reference (18.75 ± 
0.22) of the original length is the mean muscle length of the control group on the 
CLAT side, represented here by the grey dashed line. (a) OP side: Constantly signifi-
cant reduction of muscle length from the original length over the six weeks. There are 
significant differences between the CALP and the control group in week 0 and week 
4. (b) CLAT side: Constant muscle length with no changes from the reference muscle 
length.  
b 
Muscle'Length'ov 'Time'
OPS'
'
'
'
'
*'
*'
*signiﬁcant'
a 
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5.2. Cross Sectional Area 
The CSA is quite constant over the time and there are no significant differences be-
tween the two groups. In week 0 the CSA was 14.61 ± 0.62 cm2 in the CALP group and 
15.30 ± 0.75 cm2 in the control group. Then in week 2 the CSA was 15.40 ± 0.52 cm2 in 
the CALP group and 14.59 ± 0.88 cm2 in the control group. In the further process the 
muscle area was 14.91 ± 0.54 cm2 in the CALP group and 15.27 ± 1.06 cm2 in the con-
trol group in week 4. In the last CT scans in week 6 the CSA was 13.54 ± 0.62 cm2 in 
the CALP group and 13.44 ± 0.79 cm2 in the control group. (Figure 10a) 
On the CLAT side the area remains constant over the six weeks. There are no signifi-
cant changes, neither from the original area nor between the two groups. (Figure 10b) 
5.3. Fatty Muscle Infiltration 
5.3.1. Coronal 
The coronal muscle density decreases persistently over the six weeks on the OP side. 
There is an overall reduction from the start value except in week 0 in the CALP group, 
where the density remains constant. In week 0 the coronal muscle density was 53.91 ± 
9.6 HU in the CALP group and 51.39 ± 1.08 HU control group, but there is no signifi-
cance in the difference between the two intervention groups. In week 2 the density was 
46.21 ± 1.06 HU in the CALP group and 49.86 ± 0.93 HU control group. There is a sig-
nificant difference between the two groups (P < 0.5). In week 4 the density was 44.22 ± 
1.67 HU in the CALP group while it was 44.32 ± 1.17 HU in the control group. There 
were no significant differences between the two groups. Then in week 6 the density was 
41.63 ± 1.63 HU in the CALP group and 43.04 ± 1.81 HU in the control group, with no 
significant differences. (Figure 11a) 
The CLAT side shows comparatively no significant difference between the two interven-
tion groups. (Figure 11b)  
5.3.1. Transverse  
In both groups the density in the transverse plane decreases after week 0 over time. 
Overall there is no significant difference between the CALP and the control group.  
Directly after tendon release in week 0 the density was 50.10 ± 0.85 HU in the CALP 
group and 51.04 ± 1.00 HU in the control group. Then in week 2 the density was 42.25 
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± 1.30 HU in the CALP group and 46.18 ± 1.03 HU in the control group. In further pro-
gress in week 4 the density was 38.43 ± 0.85 HU in the CALP group and 41.47 ± 1.48 
HU in the control group. Finally in week 6 the density was 35.45 ± 1.87 HU in the CALP 
group and 37.06 ± 2.73 HU in the control group. (Figure 12a) 
On the CLAT side the density also shows no significant difference between the two 
groups and remains mainly constant. (Figure 12b)  
5.4. Retraction 
In week 0 the retraction of the bone fragment is 0.37 ± 0.03 cm in the CALP group and 
0.70 ± 0.23 cm in the control group. There is a significant difference between the groups 
(P < 0.05).  While in week 2, 4 and 6 there are no significant differences. In week 2 the 
retraction is 0.86 ± 0.09 cm in the CALP group and 1.01 ± 0.27 cm in the control group. 
The retraction increases further and in week 4 it is 1.19 ± 0.19 cm in the CALP group 
and 1.40 ± 0.34 cm in the control group. Finally in week 6 the retraction is 1.50 ± 0.19 
cm in the CALP group and 1.64 ± 0.28 cm in the control group. (Figure 13) 
 
 
Figure 10. Mean CSA over time measured in CT. As reference (15.20 ± 0.66) 
of the original area served the mean muscle area of the control group on the CLAT 
side, represented here by the grey dashed line. (a) OPS side: Overall there are no 
significant differences between the CALP and the control group. Constant area with 
no change from reference area except in week 6 in CALP group. (b) CLAT side: 
Constant area with no change from reference area. Overall there are no significant 
differences between the CALP and the control group. 
Coronary'Area'over'Time'
OPS'
Coronary'Area'over'Time'
KLAT'
b a 
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Coronary'Denseness'[HU]'over'Time'
OPS'
'
'
'
*'
*signiﬁcant'
Coronary'Denseness'[HU]'over'Time'
KLAT'
'
'
'
Figure 11. Mean coronal density over time measured in CT. As reference (54.79 ± 
0.59) of the original density served the mean muscle density of the control group on 
the CLAT side in week 0, represented here by the grey dashed line. (a) OP side: 
Constant reduction of the density over the six weeks. Overall there are no significant 
differences between the CALP and the control group except in week 2, where the 
CALP group shows a lower density. (b) CLAT side: Constant muscle density. Overall 
there are no significant differences between the CALP and the control group. 
b a 
Figure 12. Mean transverse muscle density over time measured in CT. As refer-
ence (49.22 ± 0.78) of the original density served the mean muscle density of the 
control group on the CLAT side in week 0, represented here by the grey dashed line. 
(a) OP side: In both groups the density decreases over time. There are no significant 
differences between the groups. (b) CLAT side: Mainly constant muscle density. 
Overall there are no significant differences between the CALP and the control group. 
 
b a 
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Retrac'on*of*Bone*Fragment*over*Time*
OPS*
* **
*signiﬁcant*
Figure 13. Mean fracture fragment 
retraction over time measured in CT. 
Constant increase of retraction over the 
six weeks. There are significant differ-
ences between the CALP and the con-
trol group in week 0. 
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Table 2  week 0 week 2 week 4 week 6 
OP Reference CALP control P  CALP control P  CALP control P  CALP control P  
Muscle length 
[cm] 
18.75 ± 
0.22 
16.38 ± 
0.17 
15.51 ± 
0.39 
0.028 15.58 ± 
0.12 
14.87 ± 
0.44 
0.177 15.35 ± 
0.16 
14.45 ± 
0.31 
0.011 
 
14.87 ± 
0.13 
14.20 ± 
0.42 
0.179 
CSA [cm2] 15.20 ± 
0.66 
14.61 ± 
0.62  
15.30 ± 
0.75 
0.509 15.40 ± 
0.52 
14.59 ± 
0.88 
0.409 14.91 ± 
0.54 
15.27 ± 
1.06 
0.744 13.54 ± 
0.62 
13.44 ± 
0.79 
0.923 
Fatty muscle 
infiltration [HU] 
• coronal 
 
• transverse 
 
54.79 ± 
0.59 
 
53.91 ± 
0.96 
 
51.39 ± 
1.08 
 
0.128 
 
46.21 ± 
1.06 
 
49.86 ± 
0.93 
 
0.042 
 
44.22 ± 
1.67 
 
44.32 ± 
1.17 
 
0.969 
 
41.63 ± 
1.63 
 
43.04 ± 
1.81 
 
0.593 
49.22 ± 
0.78 
50.10 ± 
0.85 
51.04 ± 
1.00 
0.508 42.25 ± 
1.30 
46.18 ± 
1.03 
0.067 38.43 ± 
0.85 
41.47 ± 
1.48 
0.073 35.45 ± 
1.87 
37.06 ± 
2.73 
0.626 
Retraction [cm] 0.70 ± 0.23 0.37 ± 
0.03 
0.70 ± 
0.23 
0.018 0.86 ± 
0.09 
1.01 ± 
0.27 
0.820 1.19 ± 
0.19 
1.40 ± 
0.34 
0.591 1.50 ± 
0.19 
1.64 ± 
0.28 
0.591 
CLAT Reference CALP control P  CALP control P  CALP control P  CALP control P  
Muscle length 
[cm] 
18.75 ± 
0.22 
19.19 ± 
0.19 
18.75 ± 
0.22 
0.187 19.16 ± 
0.25 
18.53 ± 
0.22 
0.130 19.13 ± 
0.27 
18.42 ± 
0.28 
0.111 19.10 ± 
0.29 
18.68 ± 
0.36 
0.387 
CSA [cm2] 15.20 ± 
0.66 
14.40 ± 
0.52 
15.20 ± 
0.66 
0.375 14.46 ± 
0.51 
15.06 ± 
0.75 
0.291 14.78 ± 
0.45 
15.40 ± 
0.98 
0.519 14.85 ± 
0.60 
15.37 ± 
1.03 
0.646 
Fatty muscle 
infiltration [HU] 
• coronal 
 
54.79 ± 
0.59 
 
54.41 ± 
1.00 
 
54.79 ± 
0.59 
 
0.820 
 
51.47 ± 
1.67 
 
52.99 ± 
1.14 
 
0.555 
 
52.30 ± 
1.67 
 
50.58 ± 
1.27 
 
0.498 
 
51.83 ± 
1.56 
 
52.92 ± 
2.26 
 
0.437 
• transverse 49.22 ± 
0.78 
48.00 ± 
0.79 
49.22 ± 
0.78 
0.344 45.27 ± 
1.30 
48.37 ± 
1.34 
0.156 47.33 ± 
1.19 
47.15 ± 
1.45 
0.927 46.21 ± 
1.26 
49.05 ± 
2.03 
0.216 
Table 2.  Effect of calpeptin on different parameters over time. Data refer to mean ± standard error, p-values for the effects of cal-
peptin on different muscle related parameters based on an unpaired t test. 
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6. Discussion 
6.1. Main Results 
Muscle length decreases over the time in both groups, whereas only in the early phase 
a difference in favour of the CALP group can be shown. The muscle seems to be para-
lysed by the calpain inhibitor and therefore shows a weaker contraction as the control 
group.  
The CSA decreases drastically beyond four weeks of tendon release in both groups. 
This supports the assumption that muscle atrophy has occurred.  
Decrease of densities in the coronal as well as in the transverse plane can already be 
observed early, whereas no difference appears between the two groups. This means 
fatty infiltration has taken place in both groups independently of the medication. 
The retraction increases over time in both groups. Since CALP reduces the muscle 
strength, the muscle retracts less in the CALP group compared to the control group. 
Nonetheless differences between the two groups appear only in the early stages. 
 
The CLAT side, which served as control, doesn’t show any irregularities and all parame-
ters remain mostly constant as expected, given that no interventions were performed. 
6.2. Strengths and Shortcomings 
The measurements of the fatty muscle infiltration were made only in one slice of the 
muscle and with the assumption that the Hounsfield Units reflect the fatty infiltration.  
It was not histologically validated. 
As well the measures of muscle CSA may underestimate the loss in muscle material, 
which can occur through a reduced length of muscle.  
6.3. Implications 
The results show that the muscle retracts very quickly and this has probably an associa-
tion with calpain. Since mechanical factors regulate the muscle mass, there is a possi-
bility of calpeptin, by sustaining the muscle length, preventing degenerative process.  
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Given that the retraction of the muscle is a problem for muscle reconstruction, the im-
mediate application of calpeptin expands the time span for successful surgical proce-
dure.  
This is especially relevant given that the prevalence of rotator cuff tears in human is 
20.7% increasing with age [18]. 
6.4. Unanswered Questions 
Our results do not expose the mechanism underlying the reduced muscle retraction by 
calpeptin. 
Possibly different mechanisms contribute to the early and late effects of calpeptin, such 
as reduced contractility and loss of muscle material (atrophy).  
6.5. Conclusion 
With calpeptin a positive effect on muscle length and retraction can be shown mainly in 
the first hour after tendon release. 
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